Clinical trialNCT01822522CompletedPhase 1Interventional

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

SponsorNational Cancer Institute (NCI)Enrollment36Advanced Malignant Solid NeoplasmHIV InfectionMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmUnresectable Solid Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Missak Haigentz
AIDS Malignancy Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uc San Diego Moores Cancer Center
La Jolla, California, United States
Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Ucla Center for Clinical Aids Research and Education
Los Angeles, California, United States
Uc San Diego Medical Center - Hillcrest
San Diego, California, United States
University of Hawaii Cancer Center
Honolulu, Hawaii, United States
Louisiana State University
Lafayette, Louisiana, United States
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Siteman Cancer Center at Washington University
St Louis, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Ben Taub General Hospital
Houston, Texas, United States
Thomas Street Clinic
Houston, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Harborview Medical Center
Seattle, Washington, United States
Virginia Mason Medical Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cabozantinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jun 2013
Primary completion: 22 May 2019
Completion: 12 May 2021
Last update posted: 10 Jan 2023
Registered enrollment: 36
Registry id: NCT01822522

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.